Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Income from Continuing Operations (2022 - 2025)

Historic Income from Continuing Operations for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $42.0 million.

  • Indivior Pharmaceuticals' Income from Continuing Operations rose 9090.91% to $42.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.0 million, marking a year-over-year increase of 13888.89%. This contributed to the annual value of $7.0 million for FY2024, which is 10555.56% up from last year.
  • According to the latest figures from Q3 2025, Indivior Pharmaceuticals' Income from Continuing Operations is $42.0 million, which was up 9090.91% from $18.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Income from Continuing Operations ranged from a high of $85.0 million in Q2 2023 and a low of -$329.0 million during Q4 2022
  • Over the past 4 years, Indivior Pharmaceuticals' median Income from Continuing Operations value was $45.0 million (recorded in 2025), while the average stood at -$5.8 million.
  • The largest annual percentage gain for Indivior Pharmaceuticals' Income from Continuing Operations in the last 5 years was 12066.87% (2023), contrasted with its biggest fall of 43880.6% (2023).
  • Indivior Pharmaceuticals' Income from Continuing Operations (Quarter) stood at -$329.0 million in 2022, then soared by 120.67% to $68.0 million in 2023, then crashed by 69.12% to $21.0 million in 2024, then surged by 100.0% to $42.0 million in 2025.
  • Its Income from Continuing Operations was $42.0 million in Q3 2025, compared to $18.0 million in Q2 2025 and $48.0 million in Q1 2025.